ADMA Biologics Inc (ADMA)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	197,673	68,132	34,788	-3,645	-28,240	-22,827	-40,292	-47,686	-65,905	-70,322	-73,135	-78,275	-71,647	-74,406	-73,610	-74,883	-75,748	-66,901	-61,422	-54,456
Total stockholders’ equity	US$ in thousands	349,018	231,890	188,269	153,706	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336
ROE		56.64%	29.38%	18.48%	-2.37%	-20.89%	-15.07%	-27.45%	-32.74%	-43.37%	-70.05%	-63.93%	-61.67%	-50.75%	-72.39%	-65.96%	-66.56%	-85.83%	-93.73%	-79.89%	-56.53%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $197,673K ÷ $349,018K
= 56.64%

ADMA Biologics Inc's return on equity (ROE) experienced a significant downward trend from March 2020 to June 2023, with negative ROE percentages ranging from -56.53% to -27.45%. During this period, the company faced challenges in generating profits relative to its shareholders' equity.

However, there was a notable improvement in ROE starting from September 2023, when the percentage moved into positive territory at 29.38% by September 30, 2024, and further increased to 56.64% by December 31, 2024. This turnaround indicates that the company's profitability relative to shareholders' equity has significantly improved, reflecting a more efficient use of equity to generate profits.

It is essential for investors and stakeholders to continue monitoring ADMA Biologics Inc's ROE to assess the sustainability of this positive trend and determine the company's ability to generate returns on shareholder investments in the long term.